💨 Abstract

Huzaifa Khorakiwala, Executive Director of Wockhardt Limited, expressed concerns about potential US tariffs on Indian pharmaceutical products, stating they pose a significant challenge to the industry. He also announced Wockhardt's advancement in antibiotic research, with their blockbuster product WCK-5222-ZENIC showing 97% success in phase 3 clinical trials.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖